Acadia Pharmaceuticals Reports Positive Trial Results

Acadia Pharmaceuticals Inc. (ACAD) reported positive Phase II trial results for its schizophrenia treatment ACP-103. The stock price more than doubled by leaping $6.92 to close at $13.61.